DOCSLIB.ORG

45 Part 606—Current Good Man- Ufacturing Practice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Food and Drug Administration, HHS Pt. 606 a presentation. The presiding officer ucts approved under § 601.91, the re- may, as a matter of discretion, permit strictions would no longer apply when questions to be submitted to the pre- FDA determines that safe use of the bi- siding officer for response by a person ological product can be ensured making a presentation. through appropriate labeling. FDA also (f) Judicial review. The Commissioner retains the discretion to remove spe- of Food and Drugs’ decision constitutes cific postapproval requirements upon final agency action from which the ap- review of a petition submitted by the plicant may petition for judicial re- sponsor in accordance with § 10.30 of view. Before requesting an order from a this chapter. court for a stay of action pending re- view, an applicant must first submit a PART 606—CURRENT GOOD MAN- petition for a stay of action under § 10.35 of this chapter. UFACTURING PRACTICE FOR BLOOD AND BLOOD COMPO- [67 FR 37996, May 31, 2002, as amended at 70 NENTS FR 14984, Mar. 24, 2005] § 601.93 Postmarketing safety report- Subpart A—General Provisions ing. Sec. Biological products approved under 606.3 Definitions. this subpart are subject to the post- marketing recordkeeping and safety Subpart B—Organization and Personnel reporting applicable to all approved bi- ological products. 606.20 Personnel. § 601.94 Promotional materials. Subpart C—Plant and Facilities For biological products being consid- 606.40 Facilities. ered for approval under this subpart, unless otherwise informed by the agen- Subpart D—Equipment cy, applicants must submit to the agency for consideration during the 606.60 Equipment. preapproval review period copies of all 606.65 Supplies and reagents. promotional materials, including pro- motional labeling as well as advertise- Subpart E [Reserved] ments, intended for dissemination or Subpart F—Production and Process publication within 120 days following Controls marketing approval. After 120 days fol- lowing marketing approval, unless oth- 606.100 Standard operating procedures. erwise informed by the agency, the ap- 606.110 Plateletpheresis, leukapheresis, and plicant must submit promotional ma- plasmapheresis. terials at least 30 days prior to the in- tended time of initial dissemination of Subpart G—Additional Labeling Standards the labeling or initial publication of for Blood and Blood Components the advertisement. 606.120 Labeling, general requirements. § 601.95 Termination of requirements. 606.121 Container label. 606.122 Circular of information. If FDA determines after approval under this subpart that the require- Subpart H—Laboratory Controls ments established in §§ 601.91(b)(2), 601.92, and 601.93 are no longer nec- 606.140 Laboratory controls. essary for the safe and effective use of 606.145 Control of bacterial contamination a biological product, FDA will so no- of platelets. tify the applicant. Ordinarily, for bio- 606.151 Compatibility testing. logical products approved under § 601.91, these requirements will no Subpart I—Records and Reports longer apply when FDA determines 606.160 Records. that the postmarketing study verifies 606.165 Distribution and receipt; procedures and describes the biological product’s and records. clinical benefit. For biological prod- 606.170 Adverse reaction file. 45 VerDate Sep<11>2014 11:11 May 16, 2017 Jkt 241076 PO 00000 Frm 00055 Fmt 8010 Sfmt 8010 Q:\21\21V7.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 606.3 21 CFR Ch. I (4–1–17 Edition) 606.171 Reporting of product deviations by (j) Compatibility testing means the licensed manufacturers, unlicensed reg- procedures performed to establish the istered blood establishments, and trans- matching of a donor’s blood or blood fusion services. components with that of a potential re- AUTHORITY: 21 U.S.C. 321, 331, 351, 352, 355, cipient. 360, 360j, 371, 374; 42 U.S.C. 216, 262, 263a, 264. (k) Distributed means: SOURCE: 40 FR 53532, Nov. 18, 1975, unless (1) The blood or blood components otherwise noted. have left the control of the licensed manufacturer, unlicensed registered Subpart A—General Provisions blood establishment, or transfusion service; or § 606.3 Definitions. (2) The licensed manufacturer has As used in this part: provided Source Plasma or any other (a) Blood means a product that is a blood component for use in the manu- fluid containing dissolved and sus- facture of a licensed biological product. pended elements which was collected (l) Control means having responsi- from the vascular system of a human. bility for maintaining the continued (b) Unit means the volume of blood or safety, purity, and potency of the prod- one of its components in a suitable vol- uct and for compliance with applicable ume of anticoagulant obtained from a product and establishment standards, single collection of blood from one and for compliance with current good donor. manufacturing practices. (c) Blood component means a product [40 FR 53532, Nov. 18, 1975, as amended at 64 containing a part of human blood sepa- FR 45370, Aug. 19, 1999; 65 FR 66635, Nov. 7, rated by physical or mechanical means. 2000; 66 FR 1835, Jan. 10, 2001; 66 FR 40889, (d) Plasma for further manufacturing Aug. 6, 2001; 72 FR 45886, Aug. 16, 2007; 80 FR means that liquid portion of blood sep- 29894, May 22, 2015] arated and used as material to prepare another product. Subpart B—Organization and (e) Plasmapheresis means the proce- Personnel dure in which blood is removed from the donor, the plasma is separated § 606.20 Personnel. from the formed elements and at least (a) [Reserved] the red blood cells are returned to the (b) The personnel responsible for the donor. collection, processing, compatibility (f) Plateletpheresis means the proce- testing, storage or distribution of blood dure in which blood is removed from a or blood components shall be adequate donor, a platelet concentrate is sepa- in number, educational background, rated, and the remaining formed ele- training and experience, including pro- ments are returned to the donor along fessional training as necessary, or com- with a portion of the residual plasma. bination thereof, to assure competent (g) Leukapheresis means the proce- performance of their assigned func- dure in which blood is removed from tions, and to ensure that the final the donor, a leukocyte concentrate is product has the safety, purity, po- separated, and the remaining formed tency, identity and effectiveness it pur- elements and residual plasma are re- ports or is represented to possess. All turned to the donor. personnel shall have capabilities com- (h) Facilities means any area used for mensurate with their assigned func- the collection, processing, compat- tions, a thorough understanding of the ibility testing, storage or distribution procedures or control operations they of blood and blood components. perform, the necessary training or ex- (i) Processing means any procedure perience, and adequate information employed after collection, and before concerning the application of pertinent or after compatibility testing of blood, provisions of this part to their respec- and includes the identification of a tive functions. unit of donor blood, the preparation of (c) Persons whose presence can ad- components from such unit of donor versely affect the safety and purity of blood, serological testing, labeling and the products shall be excluded from associated recordkeeping. areas where the collection, processing, 46 VerDate Sep<11>2014 11:11 May 16, 2017 Jkt 241076 PO 00000 Frm 00056 Fmt 8010 Sfmt 8010 Q:\21\21V7.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 606.60 compatibility testing, storage or dis- (9) The orderly conduction of all tribution of blood or blood components packaging, labeling and other finishing is conducted. operations. (b) Provide adequate lighting, ven- [40 FR 53532, Nov. 18, 1975, as amended at 49 tilation and screening of open windows FR 23833, June 8, 1984; 55 FR 11014, Mar. 26, 1990; 62 FR 53538, Oct. 15, 1997] and doors. (c) Provide adequate, clean, and con- venient handwashing facilities for per- Subpart C—Plant and Facilities sonnel, and adequate, clean, and con- venient toilet facilities for donors and § 606.40 Facilities. personnel. Drains shall be of adequate Facilities shall be maintained in a size and, where connected directly to a clean and orderly manner, and shall be sewer, shall be equipped with traps to of suitable size, construction and loca- prevent back-siphonage. tion to facilitate adequate cleaning, (d) Provide for safe and sanitary dis- maintenance and proper operations. posal for the following: The facilities shall: (1) Trash and items used during the (a) Provide adequate space for the collection, processing and compat- following when applicable: ibility testing of blood and blood com- (1) Private and accurate examina- ponents. tions of individuals to determine their (2) Blood and blood components not eligibility as blood donors. suitable for use or distribution. (2) The withdrawal of blood from do- [40 FR 53532, Nov. 18, 1975, as amended at 80 nors with minimal risk of contamina- FR 29895, May 22, 2015] tion, or exposure to activities and equipment unrelated to blood collec- Subpart D—Equipment tion. (3) The storage of blood or blood com- § 606.60 Equipment. ponents pending completion of tests. (a) Equipment used in the collection, (4) The quarantine storage of blood or processing, compatibility testing, stor- blood components in a designated loca- age and distribution of blood and blood tion pending repetition of those tests components shall be maintained in a that initially gave questionable sero- clean and orderly manner and located logical results. so as to facilitate cleaning and mainte- (5) The storage of finished products nance. The equipment shall be ob- prior to distribution. served, standardized and calibrated on (6) The quarantine storage, handling a regularly scheduled basis as pre- and disposition of products and re- scribed in the Standard Operating Pro- agents not suitable for use.
Recommended publications
  • Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’

    Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’

    Vol. 4, 311-316, February 1998 Clinical Cancer Research 311 Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma’ Craig H. Moskowitz,2 Jill R. Glassman, (median, 13 versus 22 days; P 0.06). Patients who received 1l cycles of chemotherapy prior to PBPC mobilization David Wuest, Peter Maslak, Lilian Reich, tended to have delayed platelet recovery to >20,090/&l and Anthony Gucciardo, Nancy Coady-Lyons, to require more platelet transfusions than less extensively Andrew D. Zelenetz, and Stephen D. Nimer pretreated patients (median, 13.5 versus 23.5 days; P 0.15; Division of Hematologic Oncology, Department of Medicine median number of platelet transfusion episodes, 13 versus 9; [C. H. M., D. W., P. M., L. R., A. G., N. C-L., A. D. Z., S. D. N.] and P = 0.17). Department of Biostatistics [J. R. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021 These data suggest that current strategies to mobilize PBPCs may be suboptimal in patients who have received either stem cell-toxic chemotherapy or 11 cycles of chem- ABSTRACT otherapy prior to PBPC mobilization. Alternative ap- The objective of this study was to identify factors asso- proaches, such as ex vivo expansion or the use of other ciated with poor mobilization of peripheral blood progenitor growth factors in addition to G-CSE, may improve mobili- cells (PBPCs) or delayed platelet engraftment after high- zation of progenitor cells for PBPC transplantation. dose therapy and autologous stem cell transplantation in patients with lymphoma. INTRODUCTION Fifty-eight patients with Hodgkin’s disease or non- The use of high-dose chemoradiotherapy supported by Hodgkin’s lymphoma underwent PBPC transplantation as cryopreserved autologous hematopoietic progenitor cells is ef- the “best available therapy” at Memorial Sloan-Kettering fective in treating relapsed HD3 and NHL; a high complete Cancer Center (New York, NY) between 1993 and 1995.
  • 0985.03CC Non-Mobilized Donor Consent

    0985.03CC Non-Mobilized Donor Consent

    Fred Hutchinson Cancer Research Center Consent to take part in a research study: 985.03CC – Non-Mobilized Donor Consent to Participate as a Donor of Non-Mobilized Peripheral Blood Mononuclear Cells for Laboratory Research and Process Development Studies. Principal Investigator: Derek Stirewalt, MD, Member, FHCRC, (206 667-5386) Investigators: Michael Linenberger, M.D., FACP Professor, Division of Hematology, UW, Robert & Phyllis Henigson Endowed Chair, Program Director, Hematology/Oncology Fellowship Medical Director, Apheresis and Cellular Therapy, SCCA, Member, FHCRC, Associate Professor of Medicine, UW, (206 667-5021); Laura Connelly Smith, Assistant Member, FHCRC, Assistant Professor, UW (206 606 -6938) Research Coordinator: Aubrey McMillan, (206) 667-3539 Emergency Phone (24 hours) UW Transplant unit 8NE: (206) 598-8902 UW Nocturnist on call provider (7:00 PM -7:00 AM): (206) 598-1062 Donor recruitment and participation: 206-667-5318 Important things to know about this study. You are invited to participate in a research study. The purpose of this research is to collect blood cells by a procedure called “leukapheresis”. Leukapheresis is a procedure that allows for a greater collection of peripheral blood cells than can be obtained by standard blood donation. Our purpose is to collect both small blood draws and larger samples of peripheral blood cells for laboratory research studies. This research may involve analysis of your genetic material called DNA and RNA. The studies may also examine other components of the cell like proteins. These analyses can be used to better understand cancer and other diseases. People who agree to join the study will be asked to attend 2 appointments over up to 30 days.
  • Leukapheresis Protocol for Nonhuman Primates Weighing Less Than 10 Kg

    Leukapheresis Protocol for Nonhuman Primates Weighing Less Than 10 Kg

    Journal of the American Association for Laboratory Animal Science Vol 52, No 1 Copyright 2013 January 2013 by the American Association for Laboratory Animal Science Pages 70–77 Leukapheresis Protocol for Nonhuman Primates Weighing Less than 10 Kg Vimukthi Pathiraja, Abraham J Matar, Ashley Gusha, Christene A Huang, and Raimon Duran-Struuck* Leukapheresis is a common procedure for hematopoietic cell transplantation in adults. The main challenge in applying this procedure to human infants and small monkeys is the large extracorporeal blood volume (165 mL on average) necessary for priming the apheresis machine. This volume represents greater than 50% of the total circulating blood volume of a human neonate or small monkey. In this report, we document a safe leukapheresis protocol developed for rhesus macaques (3.9 to 8.7 kg). To avoid sensitizing donor animals undergoing leukapheresis to third-party blood products, autologous blood col- lected during the weeks prior to leukapheresis was used to volume-expand the same donor while priming the machine with saline on the day of leukapheresis. During the procedures, blood pressure was controlled by monitoring the inlet volume, and critical-care support was provided by the anesthesia team. Electrolytes and hemogram parameters were monitored intermit- tently. Overall, our research subjects underwent effective 4- to 6-h leukapheresis. A total of 9 leukapheresis procedures were performed, which yielded 1 × 109 to 6 × 109 peripheral blood mononuclear cells containing 1.1 to 5.1 × 106 CD34+ cells (assessed in 4 of 9 macaques) in a volume of 30 to 85 mL. All macaques showed decreases in Hct and platelet counts.
  • Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL Or ALL

    Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL Or ALL

    cells Article Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL Felix Korell 1,*, Sascha Laier 2, Sandra Sauer 1, Kaya Veelken 1, Hannah Hennemann 1, Maria-Luisa Schubert 1, Tim Sauer 1, Petra Pavel 2, Carsten Mueller-Tidow 1, Peter Dreger 1, Michael Schmitt 1 and Anita Schmitt 1 1 Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany; [email protected] (S.S.); [email protected] (K.V.); [email protected] (H.H.); [email protected] (M.-L.S.); [email protected] (T.S.); [email protected] (C.M.-T.); [email protected] (P.D.); [email protected] (M.S.); [email protected] (A.S.) 2 Institute of Clinical Transfusion Medicine and Cell Therapy (IKTZ), 89081 Heidelberg, Germany; [email protected] (S.L.); [email protected] (P.P.) * Correspondence: [email protected] Received: 9 April 2020; Accepted: 13 May 2020; Published: 15 May 2020 Abstract: Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total of 75 unstimulated leukaphereses were analyzed including 45 aphereses in patients and 30 in healthy donors. Thereof, 41 adult patients with Non-Hodgkin’s lymphoma (85%) or acute lymphoblastic leukemia (15%) underwent leukapheresis for CAR-T cell production.
  • Transfusion Reactions 7

    Transfusion Reactions 7

    HEMATOLOGY Immunohematology, transfusion medicine and bone marrow transplantation Institute of Pathological Physiology First Facultry of Medicine, Charles University in Prague http://patf.lf1.cuni.cz Questions and Comments: MUDr. Pavel Klener, Ph.D., [email protected] Presentation in points 1. Imunohematology 2. AB0 blood group system 3. Rh blood group system 4. Hemolytic disease of the newborn and neonatal alloimmune thrombocytopenia 5. Pre-transfusion examinations 6. Transfusion reactions 7. Transfusion medicine and hemapheresis 8. HLA system 9. Stem cell/ bone marrow transplantation Origins of immunohematology and transfusion medicine Imunohematology as a branch of medicine developed hand in hand with the origins of transfusion therapy. It focuses on concepts and questions associated with transfusion therapy, immunisation (as a result of transfusion therapy and pregnancy) and organ transplantation. In 1665, an English physiologist, Richard Lower, successfully performed the first animal- to-animal blood transfusion that kept ex-sanguinated dogs alive by transfusion of blood from other dogs. In 1667, Jean Bapiste Denys, transfused blood from the carotid artery of a lamb into the vein of a young man, which at first seemed successful. However, after the third transfusion of lamb’s blood the man suffered a reaction and died. Due to the many disastrous consequences resulting from blood transfusion, transfusions were prohibited from 1667 to 1818- when James Blundell of England successfully transfused human blood to women suffering from hemorrhage at childbirth. Revolution in 1900 In 1900 Karl Landsteiner discovered the AB0 blood groups. This landmark event initiated the era of scientific – based transfusion therapy and was the foundation of immunohematology as a science.
  • How Do I Perform Whole Blood Exchange?

    How Do I Perform Whole Blood Exchange?

    HOW DO I? How do I perform whole blood exchange? † † † David Ming-Hung Lin ,1, Joanne Becker,2, YanYun Wu,1 and Laura Cooling3, here are a number of clinical scenarios in which crossmatched against plasma or adsorbed plasma, if avail- simultaneous exchange of the patient’s plasma able. Because preparation of reconstituted WB is considered and red blood cells (RBCs) are indicated. Some of an open system with a 24-hour outdate, we prepared only these clinical indications for therapeutic whole one reconstituted WB unit at a time (i.e., after dispensing Tblood exchange (WBEx) include hemolytic disease of the one unit, the next unit was prepared). WBEx was performed newborn, severe autoimmune hemolytic anemia (AIHA), by physically removing WB with a syringe, followed by infu- – babesiosis, sickle cell disease, and hyperleukocytosis.1 4 sion of reconstituted WB. In adult patients, this involved WBEx has been performed with manual, semiautomated, removal of 200 mL (50 mL per draw with 60-mL syringes) and fully automated methods using replacements fluids over 10 minutes through a triple-lumen central venous (i.e., RBCs with plasma, RBCs with 5% albumin, and whole catheter, followed by infusion of WB over 1 to 1.5 hours. blood [WB]) reconstituted to a prespecified target hemato- Overall, it required 20 hours to complete a manual WBEx crit (Hct); however, methodologies vary widely and each exchange with 12 units of WB as replacement. For pediatric carry advantages and disadvantages. Here, we describe our patients, a similar process was followed using a central or combined experiences in performing WBEx, including clini- femoral venous catheter (5 mL/kg per draw).
  • Leukopak PBMC Sample Processing for Preparing Quality Control Material to Support Proficiency Testing Programs

    Leukopak PBMC Sample Processing for Preparing Quality Control Material to Support Proficiency Testing Programs

    JIM-11874; No of Pages 8 Journal of Immunological Methods xxx (2014) xxx–xxx Contents lists available at ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs Ambrosia Garcia a, Sarah Keinonen a, Ana M. Sanchez a, Guido Ferrari a,d,e, Thomas N. Denny a,b,e, M. Anthony Moody a,c,⁎ a Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA b Departments of Medicine, Duke University Medical Center, Durham, NC, USA c Departments of Pediatrics, Duke University Medical Center, Durham, NC, USA d Departments of Surgery, Duke University Medical Center, Durham, NC, USA e Duke Global Health Institute, Duke University Medical Center, Durham, NC, USA article info abstract Article history: External proficiency testing programs designed to evaluate the performance of end-point Received 19 November 2013 laboratories involved in vaccine and therapeutic clinical trials form an important part of Received in revised form 14 May 2014 clinical trial quality assurance. Good clinical laboratory practice (GCLP) guidelines recommend Accepted 31 May 2014 both assay validation and proficiency testing for assays being used in clinical trials, and such Available online xxxx testing is facilitated by the availability of large numbers of well-characterized test samples. These samples can be distributed to laboratories participating in these programs and allow Keywords: monitoring of laboratory performance over time and among participating sites when results Proficiency testing are obtained with samples derived from a large master set. The leukapheresis procedure Leukocytes provides an ideal way to collect samples from participants that can meet the required number Leukapheresis of cells to support these activities.
  • Leukapheresis: an Overview

    Leukapheresis: an Overview

    IMPORTANCE OF IMMUNE CELLS IN RESEARCH Your immune cell donation may assist researchers to advance medical treatments, lead to a scientific breakthrough or even develop cures for certain diseases or disorders. Immunologists worldwide have a need for high quality immune cells and cellular subsets, and this is where you come in! Researchers will use donations like yours in an attempt to find novel ways to prime the immune system against cancers and other diseases such as HIV, auto-immune disorders, multiple sclerosis, Crohn’s, CONTACT US allergies and asthma. Immunotherapy treatments are especially effective against lung cancer, skin cancer and blood cancers such (267) 310-1400 LEUKAPHERESIS: as leukemia and lymphoma. [email protected] AN OVERVIEW biospecialty.com WHITE BLOOD CELL DONATION PROCESS Blood is made up of many components, specifically platelets, red blood cells, plasma and white blood cells, which can all be Biological Specialty Company individually collected. FDA-registered donor center operating under Investigational Review Board (IRB) approval 2165 N. Line Street | Colmar, PA 18915 1401 W. Green Street | Allentown, PA 18102 22 South 4th Street | Reading, PA 19602 LEUKAPHERESIS, noun leu· ka· phe· re· sis | \ ˌlü-kə-fə-ˈrē-səs\ The process of leukapheresis allows for peripheral blood Derived from the latin roots mononuclear cells (PBMCs) to be collected from the blood while returning red blood cells, platelets and plasma back to the donor. An of leuk (meaning white) and apheresis machine is used to draw blood through a vein in one arm, aphaeresis (translates to take remove the needed component and return the unneeded parts back away).
  • Peripheral Blood Stem Cell Transplantation As an Alternative to Bone Marrow Transplantation: an Overview

    Peripheral Blood Stem Cell Transplantation As an Alternative to Bone Marrow Transplantation: an Overview

    Henry Ford Hospital Medical Journal Volume 39 Number 2 Article 10 6-1991 Peripheral Blood Stem Cell Transplantation as an Alternative to Bone Marrow Transplantation: An Overview Nalini Janakiraman Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Janakiraman, Nalini (1991) "Peripheral Blood Stem Cell Transplantation as an Alternative to Bone Marrow Transplantation: An Overview," Henry Ford Hospital Medical Journal : Vol. 39 : No. 2 , 103-107. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol39/iss2/10 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Peripheral Blood Stem Cell Transplantation as an Alternative to Bone Marrow Transplantation: An Overview Nalini Janakiraman, MD' Slem cells capable of resloring hemalopoiesis following lethal bone marrow injury circulate in Ihc blood of many animals, including humans. When collected ihrough leukapheresis and reinfused following high-dose chenwiherapy, slem cells offer a Irealmenl optiim not currently open lo some patients who are unable lo undergo autologous hone marrow transplantation because of tumor involvement in the pelvis, prior pelvic radiation, or intolerance to general anesthesia. After stem cell infusion, hematologic and immunologic recovery are rapid in comparison lo that after autologous hone marrow reinfusion: however, in some cases platelet engraftment is slower. There is some evidence lhal tumor conlaminalion in the peripheral hlood is much less than in the marrow.
  • Blood Transfusions an Overview

    Blood Transfusions an Overview

    Blood Transfusions: An Overview Jassin M. Jouria, MD Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serves as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. Abstract Being able to replace blood and blood components that a patient has lost or that his or her body is not able to produce is a vital part of providing excellent medical care. With the aid of donor blood, or even sometimes the patient’s own blood that has been previously banked, medical professionals have a safe strategy for treatment of patients who have lost blood to illness or injury. This course will explain the different types of blood products, the requirements for performing a transfusion, and how to recognize and respond to complications of the transfusion process.
  • Case Reports

    Case Reports

    CASE REPORTS units that were group A, D+, E−, K−, and Fy(a−). Severe delayed hemolytic transfusion reaction Although anti-Le a was microscopically positive at poly - due to anti-Fy3 in a patient with sickle cell disease ethylene glycol (PEG) IgG, anti-Lea is not routinely undergoing red cell exchange prior to matched for at the study institution nor had been hematopoietic progenitor cell collection for gene matched for with transfusions at his primary medical therapy facility. After RCE, his Hb rose from 9.3 to 11.2 g/dL, and his HbS% decreased from 78% to 22% (HbA% of 72%). To our knowledge, most patients with sickle cell di- The following day, the patient was given a single 240 sease (SCD) who have undergone hematopoietic progen - µg/kg dose of plerixafor for HPC mobilization and started itor cell (HPC) collection for gene therapy have been con - leukapheresis about 3 hours afterward. He had no ditioned with a series of monthly simple or exchange adverse events and was discharged home after his leuka - transfusions. The rationale for this practice is to improve pheresis. safety and decrease bone marrow inflammation, poten - Five days after RCE, the patient developed throbbing + tially leading to higher CD34 mobilization and low back pain, subjective fevers, dark urine, and scleral decreased risk of adverse events during HPC collection. icterus, symptoms differing from his typical vaso-occlu - + Whether transfusion actually improves CD34 mobiliza - sive crises usually manifesting as right-sided flank/upper tion is not clear however, and we previously showed that back discomfort and priapism.
  • A Hospital Based Retrospective Study of Factors Influencing Therapeutic Leukapheresis in Patients Presenting with Hyperleukocyti

    A Hospital Based Retrospective Study of Factors Influencing Therapeutic Leukapheresis in Patients Presenting with Hyperleukocyti

    www.nature.com/scientificreports OPEN A hospital based retrospective study of factors infuencing therapeutic leukapheresis Received: 16 June 2017 Accepted: 20 November 2017 in patients presenting with Published: xx xx xxxx hyperleukocytic leukaemia Yanxia Jin1, Shishang Guo2, Qin Cui1, Sichao Chen1, Xiaoping Liu1, Yongchang Wei3,5, Yunbao Pan 4,5, Liang Tang6, Tingting Huang1, Hui Shen1, Guanghui Xu6, Xuelan Zuo1, Shangqin Liu1, Hui Xiao1, Fei Chen1, Fayun Gong6 & Fuling Zhou1,3,4 Therapeutic leukapheresis is a rapid and efective method to reduce early mortality of patients with hyperleukocytic leukaemia (HLL). However, few studies on factors infuencing the efciency have been reported. In this study, 67 cases who underwent leukapheresis were retrospectively analysed and factors related to the collection efciency of leukapheresis (CEWBC) were also evaluated. Paired t test showed that there was a signifcant decrease in statistics of white blood cell (WBC) counts after apheresis. The results of two independent samples nonparametric test suggested that WBC counts, platelet (PLT) counts, haematocrit (HCT), hemoglobin (HGB), serum chlorine (Cl) and globulin (GLB) before leukapheresis correlated with the CEWBC. Multiple linear regression analysis with background stepwise variable selection indicated that only WBC and HCT before leukapheresis had an infuence on CEWBC signifcantly. Kaplan-Meier analysis and Cox regression model indicated that lymphocyte (LY) and mean corpuscular hemoglobin (MCH) pre-apheresis as independent factors signifcantly afected the prognostic survival of patients with HLL. Moreover, platelets and red blood cell were contaminated in the product of leukapheresis. It is an urgent problem to be solved in order to realise higher efcacy and higher purity of WBC collection to improve the survival of patients with HLL through optimising instruments.